Review on influenza antiviral medicinal products for potential use during pandemic. Summary report

In May 2004, the DG Enterprise of the European Commission asked the scientific Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMEA) to compile and review scientific information on antiviral medicinal products during an influenza pandemic. The CHMP conducted the review on the basis of the information received from the Marketing Authorisation Holders for amantadine, oseltamivir and zanamivir and from the literature. The review and recommendations were submitted to the Commission in March 2005. The consensus reached at that time is summarised in this document. (Please note that the document is of a technical nature.)